Navigation Links
In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
Date:3/18/2009

Telaprevir in Combination with a Long-Acting Interferon and Ribavirin Will Earn Decision Resources' Clinical Gold Standard for Hepatitis C Virus in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., March 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists and hepatologists identify a therapy's effect on sustained virologic response in genotype 1 patients as the attribute that most influences their prescribing decisions in hepatitis C virus infection. Clinical data and the opinions of interviewed thought leaders indicate that the addition of Vertex/Janssen Pharmaceutica/Mitsubishi Tanabe's telaprevir or Schering-Plough's boceprevir to peginterferon/ribavirin provide advantages in this attribute over Roche's Pegasys (peginterferon-a-2a) plus ribavirin, the sales-leading treatment in the market.

The new report entitled Hepatitis C Virus: Protease and Polymerase Inhibitors on the Horizon to Revolutionize Treatment finds that a novel protease inhibitor that, when used in combination with peginterferon/ribavirin and achieves a significantly higher sustained virologic response in genotype 1 patients with only 24 weeks of treatment compared with the standard 48-week therapy with peginterferon/ribavirin, would earn a higher patient share in the United States than in Europe. The report finds that such an agent would earn a 60 percent patient share in the U.S. and a 40 percent patient share in Europe, according to surveyed U.S. and European gastroenterologists and hepatologists.

In 2008, Decision Resources' proprietary clinical gold standard for hepatitis C virus was Pegasys plus ribavirin because of its advantages in delivery and dosing. Based on available data and expert opinion, telaprevir plus ribavirin and a long-acting interferon will earn gold-standard status for hepatitis C virus following approval of telaprevir in 2011.

"New regimens that include a protease inhibitor, such as telaprevir or boceprevir, appear to have a competitive advantage in efficacy in patients infected with genotype 1 over the current peginterferon/ribavirin regimens," said Decision Resources Vice President John Lebbos, M.D. "Furthermore, the duration of therapy for genotype 1 patients can potentially be reduced with new three-drug regimens."

About the Report

Hepatitis C Virus: Protease and Polymerase Inhibitors on the Horizon to Revolutionize Treatment is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Decision Resources                       Decision Resources, Inc.
    Christopher Comfort                      Elizabeth Marshall
    781-296-2597                             781-296-2563
    ccomfort@dresources.com                  emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Is telmisartan effective in treating non-alcoholic steatohepatitis?
2. Varicella zoster infection causes severe autoimmune hepatitis
3. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
4. Liver transplant recipients with hepatitis B may need lifelong antiviral treatment
5. Pitt receives $11 million from NIH to coordinate hepatitis B clinical research network
6. PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine
7. Hispanics Respond Poorly to Standard Hepatitis C Therapy
8. May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?
9. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
10. Hepatitis C treatment reduces the virus but liver damage continues
11. Improved Testing for Hepatitis B Virus From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in the health ... of leaders in the nursing and health care industry. It also provides insight to ... Christian University. , As the nursing industry is coming out of one of ...
(Date:5/26/2016)... ... 26, 2016 , ... Despite last week’s media reports hinting at a June ... wait until March 2017 for an interest rate increase, according to Rajeev Dhawan of ... , “The Federal Open Market Committee (FOMC) dot charts are of interest to the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... ... 2016 , ... Connor Sports, through its Connor Cares initiative, will ... Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career ... all forms and levels of the game, Connor Sports has committed to a significantly ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... one that has a significant negative impact on long-term patient survival, reports a ... The results, published online this week in the Journal of Thoracic and Cardiovascular ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016 Cirujanos holandeses han puesto ... los médicos a compartir sus mejores prácticas por el ... Profesionales médicos de Europa, África, Asia ... la aplicación, que combina la transmisión en vivo con ... Educación   "Imagine un médico de ...
(Date:5/24/2016)... Mass. , May 24, 2016  NxStage Medical, ... technology company focused on advancing renal care, today announced ... plans to participate in the following schedule of investor ... be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, June ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... de COMBO ™ , la ... présentent des cathéters destinés à l,intervention portant ... artério-veineuse (FAV)   OrbusNeich, entreprise ... vasculaires permettant de changer la vie, a ...
Breaking Medicine Technology: